1. < Home

antibody-drug conjugate

Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis

Meric-Bernstam F, Bardia A, Bossi P, Bianchini G, Gatlin F, Lalla RV, Melosky B, Niikura N, Yap TA, Kim SS, Rajagopalan R, Fairhurst RM, Graff[...]

By sjmartinez • March 28, 2025
Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2- Metastatic Breast Cancer

Rugo HS, Bardia A, Schmid P, Tolaney SM, Dasgupta A, Kaushik A, Verret W, Gosset M, Brufsky A, Cortés J, Marmé F. Q-TWiST Analysis of[...]

By sjmartinez • March 27, 2025
Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small cell lung cancer (NSCLC) after progression on prior osimertinib

Horinouchi H, Cho BC, Camidge DR, Goto K, Tomasini P, Li Y, Vasilopoulos A, Brunsdon P, Hoffman D, Shi W, Bolotin E, Blot V, Goldman[...]

By sjmartinez • January 14, 2025
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary

Moore KN, Lorusso D, Oaknin A, Oza A, Colombo N, Van Gorp T, O'Malley DM, Banerjee S, Murphy CG, Harter P, Konecny GE, Pautier P,[...]

By sjmartinez • December 13, 2024
The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial

Secord AA, Lewin SN, Murphy CG, Cecere SC, Barquín A, Gálvez-Montosa F, Mathews CA, Konecny GE, Ray-Coquard I, Oaknin A, Pérez MJR, Bonaventura A, Diver[...]

By sjmartinez • December 2, 2024